

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

SUP-HD1

RRID:CVCL_2208

Type: Cell Line

Proper Citation

DSMZ Cat# ACC-574, RRID:CVCL_2208

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2208

Proper Citation: DSMZ Cat# ACC-574, RRID:CVCL_2208

Description: Cell line SUP-HD1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Hodgkin lymphoma

Defining Citation: [PMID:2554995](#), [PMID:8558920](#), [PMID:20628145](#), [PMID:22460905](#), [PMID:27397505](#), [PMID:29533902](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SUP-HD1

Synonyms: Sup-HD1, SUP-HD-1, SUPHD1

Cross References: CLO:CLO_0037190, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioSample:SAMN03473483, BioSample:SAMN10988468, cancercellines:CVCL_2208, Cell_Model_Passport:SIDM00422, Cosmic:1086360, Cosmic:1278831, Cosmic:1432043, Cosmic-CLP:1331039, DepMap:ACH-001203, DSMZ:ACC-574, DSMZCellDive:ACC-574, EGA:EGAS00001000978, GDSC:1331039, GEO:GSM552469, GEO:GSM887659, GEO:GSM888751, GEO:GSM1670492, IARC_TP53:30175, LINCS_LDP:LCL-2014,

PharmacDB:SUPHD1_1520_2019, PRIDE:PXD030304, Progenetix:CVCL_2208, Wikidata:Q54970875

ID: CVCL_2208

Vendor: DSMZ

Catalog Number: ACC-574

Record Creation Time: 20220427T221613+0000

Record Last Update: 20260830T000038+0000

Ratings and Alerts

No rating or validation information has been found for SUP-HD1.

No alerts have been found for SUP-HD1.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Caillot M, et al. (2023) Exportin 1-mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphoma. Molecular oncology, 17(12), 2546.